BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 01:09:45 pm | |||
| 95.25 EUR | -1.80% |
|
95.2 | -0.05% |
| May. 10 | BioMérieux: the rebound gains momentum, an analyst reinforces its case | CF |
| Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.9B 4.21B | Sales 2025 * | 4.19B 4.52B | Capitalization | 11.46B 12.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 467M 504M | Net income 2025 * | 527M 568M | EV / Sales 2024 * | 2.87 x |
| Net cash position 2024 * | 263M 284M | Net cash position 2025 * | 444M 478M | EV / Sales 2025 * | 2.63 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
22.2
x | Employees | 13,696 |
| Yield 2024 * |
0.89% | Yield 2025 * |
1.03% | Free-Float | 36.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | -0.46% | ||
| 1 week | -3.26% | ||
| Current month | -3.45% | ||
| 1 month | -8.22% | ||
| 3 months | -4.74% | ||
| 6 months | -0.83% | ||
| Current year | -4.03% |
1 week
96.40
100.90
1 month
96.40106.00
Current year
94.26108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 14 M€ | -3.61% | ||
| 0.26% | 1,083 M€ | +3.57% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 95.25 | -1.80% | 214 218 |
| 24-05-13 | 97 | -2.32% | 159,352 |
| 24-05-10 | 99.3 | +0.05% | 126,188 |
| 24-05-09 | 99.25 | +0.15% | 45,551 |
| 24-05-08 | 99.1 | -0.70% | 70,365 |
Real-time Euronext Paris, May 14, 2024 at 03:24 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
97
EUR
Average target price
113.4
EUR
Spread / Average Target
+16.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.03% | 12.37B | |
| -1.48% | 8.37B | |
| +10.04% | 5.84B | |
| +25.61% | 5.4B | |
| -4.58% | 4.37B | |
| -51.80% | 3.23B | |
| +16.25% | 2.8B | |
| +30.25% | 2.26B | |
| -4.08% | 1.87B | |
| +3.02% | 1.6B |
- Stock Market
- Equities
- BIM Stock
